GlassScriptPhysician profile
Brandy N Holder
NPI 1174153357
$1,235.59
in general payments reported to CMS, 2019-2025
23 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $212 · 2023: $159 · 2024: $471 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $192.11 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $178.53 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $118.68 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $114.43 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $88.64 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $56.60 | 2023-2025 | Gvoke Hypopen |
| Pfizer INC. | $51.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.96 | 2024 | Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.95 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.98 | 2022-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Boston Scientific Corporation | $39.48 | 2024-2025 | General - Erectile Dysfunction |
| Bayer Healthcare Pharmaceuticals INC. | $37.47 | 2023 | |
| Sanofi Pasteur INC. | $31.97 | 2025 | |
| Exact Sciences Corporation | $31.67 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $22.84 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.00 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Insulet Corporation | $18.05 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.98 | 2023 | Xifaxan |
| Dynavax Technologies Corporation | $17.84 | 2025 | Heplisav-B |
| Seqirus USA INC | $17.19 | 2025 | Fluad, Flucelvax |
| Alexion Pharmaceuticals, INC. | $16.88 | 2023 | Strensiq |
| Janssen Pharmaceuticals, INC | $14.73 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $14.40 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.